Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, Blueprint Medicines create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint Medicines have leveraged their research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, Blueprint Medicines is delivering their approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. In addition, Blueprint Medicines is globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy.